Celularity IncNASDAQ:CELUNASDAQ FSI:E. Delinquent (Issuer missed regulatory filing deadline)
- LAST PRICE1.5500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.4500/ 1
- Ask / Lots1.5900/ 16
- Open / Previous Close--- / 1.5500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CELU |
|---|---|---|
| 09:32 ET | 3462 | 1.4 |
| 09:37 ET | 600 | 1.435 |
| 09:39 ET | 100 | 1.4 |
| 09:42 ET | 300 | 1.46 |
| 09:44 ET | 100 | 1.4639 |
| 09:50 ET | 100 | 1.44 |
| 09:53 ET | 3000 | 1.4 |
| 10:09 ET | 200 | 1.43 |
| 10:15 ET | 317 | 1.45 |
| 10:26 ET | 1000 | 1.45 |
| 11:14 ET | 100 | 1.4441 |
| 11:18 ET | 200 | 1.445 |
| 12:06 ET | 100 | 1.4216 |
| 12:44 ET | 1845 | 1.41 |
| 01:02 ET | 600 | 1.468 |
| 01:04 ET | 300 | 1.4663 |
| 01:13 ET | 2600 | 1.4411 |
| 01:31 ET | 150 | 1.4262 |
| 01:40 ET | 100 | 1.4648 |
| 01:47 ET | 100 | 1.46 |
| 02:02 ET | 2173 | 1.4256 |
| 03:12 ET | 100 | 1.46 |
| 03:17 ET | 100 | 1.4698 |
| 03:19 ET | 633 | 1.48 |
| 03:26 ET | 2955 | 1.48 |
| 03:30 ET | 1983 | 1.49 |
| 03:32 ET | 4923 | 1.515 |
| 03:39 ET | 1300 | 1.51 |
| 03:44 ET | 100 | 1.45 |
| 03:57 ET | 100 | 1.54 |
| 04:00 ET | 566 | 1.55 |
Oct 23, 2024
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel, from 8:30AM ET on Wednesday Oct 23, 2024 by Dow Jones
8:30AM ET on Wednesday Oct 23, 2024 by Dow Jones
Oct 22, 2024
Celularity Provides Corporate Update, from 8:30AM ET on Tuesday Oct 22, 2024 by Dow Jones
8:30AM ET on Tuesday Oct 22, 2024 by Dow Jones
Oct 18, 2024
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal, from 6:00PM ET on Friday Oct 18, 2024 by Dow Jones
6:00PM ET on Friday Oct 18, 2024 by Dow Jones
Oct 16, 2024
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound(TM) Product from Sequence LifeScience, Inc., from 5:15PM ET on Wednesday Oct 16, 2024 by Dow Jones
5:15PM ET on Wednesday Oct 16, 2024 by Dow JonesPress Release: Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound(TM) Product from Sequence LifeScience, Inc., from 5:15PM ET on Wednesday Oct 16, 2024 by Dow Jones
5:15PM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Celularity Inc | 34.1M | -0.2x | --- |
Aadi Bioscience Inc | 48.2M | -0.8x | --- |
Prenetics Global Ltd | 53.3M | -1.2x | --- |
HOOKIPA Pharma Inc | 45.3M | -0.7x | --- |
Cara Therapeutics Inc | 16.0M | -0.1x | --- |
ImmuCell Corp | 28.1M | -6.9x | --- |
Company Information
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
Contact Information
- Headquarters
- 170 Park AveFLORHAM PARK, NJ, United States 07932
- Phone
- 908-768-2170
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer
- Robert Hariri
- Chief Financial Officer
- David Beers
- President - Degenerative Disease
- Stephen Brigido
- Senior Executive Vice President, Chief Administrative Officer, General Manager
- John Haines
- Executive Vice President, General Counsel
- K. Harold Fletcher
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $34.1M |
|---|---|
Revenue (TTM) | $33.5M |
Shares Outstanding | 22.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-8.19 |
Book Value | $2.11 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 1.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -488.89% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
